Stock Report

All about this stock under one free report Last Updated: 15-May-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Leap Therapeutics Inc. (LPTX)

Stock Card factsheet share-fund-plan-icon

$1.58

up-down-arrow $-0.47 (-22.93%)

As on 11-Dec-2025 09:30EDT

Market cap

info icon

$116 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

27.3

Div. Yield

info icon

0 %

Leap Therapeutics (LPTX) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 1.40 High: 1.61

52 Week Range

Low: 0.22 High: 3.58

Liquidityliquidity

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $0 Mln

  • ROEROE information

    -1.8 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    --

  • EV/EBITDAEV/EBITDA information

    0.5

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $-2.4

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    56,651,840

10 Years Aggregate

CFO

$-291.92 Mln

EBITDA

$-368.11 Mln

Net Profit

$-362.06 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Leap Therapeutics (LPTX)
-45.0 243.9 458.3 -50.0 -31.8 -39.6 --
BSE Sensex*
-11.1 -2.1 -8.9 -7.5 6.6 9.1 11.4
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 11-Dec-2025  |  *As on 15-May-2026  |  #As on 26-Oct-2023
Company
2024
2023
2022
2021
2020
2019
2018
Leap Therapeutics (LPTX)
-30.4 -7.9 -86.1 44.0 100.9 -44.0 -67.7
S&P Small-Cap 600
7.0 13.9 -17.4 25.3 9.6 20.9 -9.7
BSE Sensex
8.1 18.7 4.4 22.0 15.8 14.4 5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
Quarterly Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Key Ratios

View Details

5Y Avg -- 3Y Avg -- TTM --

P/E Ratio

--

--Min --Median --Max

P/B Ratio

--

--Min --Median --Max

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

Peers

View Details
Company
 Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Leap Therapeutics (LPTX)
1.6 116.1 0.4 -98.2 -10,576.5 -834.6 -- 27.3
Adverum Biotechnologies (ADVM)
4.4 96.3 -3.6 -204.4 4,048.0 -- -- 0.9
Akero Therapeutics (AKRO)
54.7 4,499.0 0.0 -292.8 -7,205,162.5 -28.7 -- 4.7

Shareholding Pattern

View Details
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Leap Therapeutics (LPTX)

Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1,...  which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.  Read more

  • CFO, General Counsel, Treasurer & Secretary, President, CEO & Director

    Mr. Douglas E. Onsi J.D.

  • CFO, General Counsel, Treasurer & Secretary, President, CEO & Director

    Mr. Douglas E. Onsi J.D.

  • Headquarters

    Cambridge, MA

  • Website

    https://www.leaptx.com

Value Research Ratings

Our rating system has guided millions of investors in the past 20 years.

Top Rated Stocks

All stocks with 5-star Value Research Ratings

Top Rated Stocks Icon

High Quality Small Caps

Small-cap stocks rated high on quality score

High Quality Small Caps Icon

High Growth Large Caps

Large-cap stocks with a high growth score

High Growth Large Caps Icon

Value Meets Momentum

Top momentum stocks with a high valuation score

Value Meets Momentum Icon

Top Rated Banks

Banks that rate high on Value Research Stock Ratings

Top Rated Banks Icon
Explore Screeners
Edit peer-selector-edit

FAQs for Leap Therapeutics (LPTX)

The share price of Leap Therapeutics Inc (LPTX) is $1.58 (NASDAQ) as of 11-Dec-2025 09:30 EDT. Leap Therapeutics Inc (LPTX) has given a return of -31.8% in the last 3 years.

Since, TTM earnings of Leap Therapeutics Inc (LPTX) is negative, P/E ratio is not available.
The P/B ratio of Leap Therapeutics Inc (LPTX) is 27.25 times as on 11-Dec-2025, a 507 premium to its peers’ median range of 4.49 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2024
-1.76
3.38
2023
-1.37
1.86
2022
-0.09
0.09
2021
-0.90
0.34
2020
-5.07
0.25

The 52-week high and low of Leap Therapeutics Inc (LPTX) are Rs 3.58 and Rs 0.22 as of 15-May-2026.

Leap Therapeutics Inc (LPTX) has a market capitalisation of $ 116 Mln as on 11-Dec-2025. As per SEBI classification, it is a Small Cap company.

Before investing in Leap Therapeutics Inc (LPTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.